Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
Inflammation01:38

Inflammation

Overview
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endothelial cell damage in patients with acute graft versus host disease receiving treatment with extracorporeal photopheresis.

Frontiers in immunology·2026
Same author

Impaired hemostasis in mechanical circulatory support systems: Monitoring with T-TAS® 01, in vitro correction with VWF concentrates, and impact of membrane oxygenators.

Heart & lung : the journal of critical care·2026
Same author

Common Biomarkers of Endothelial Dysfunction Across Highly Prevalent Diseases with Cardiovascular Risk: Functional Characterization and Prognostic Implications.

International journal of molecular sciences·2026
Same author

Diagnostic performance of flow cytometric osmotic fragility testing in hereditary spherocytosis.

Cytometry. Part B, Clinical cytometry·2026
Same author

Endothelial activation and damage associated with steroid-refractory aGVHD are counteracted by ruxolitinib.

Blood advances·2026
Same author

First-in-human tandem Terbium-161 and Actinium-225 PSMA radioligand therapy in metastatic castration-resistant prostate cancer.

European journal of nuclear medicine and molecular imaging·2026
Same journal

miR-19a and miR-20a and Tissue Factor Expression in Activated Human Peripheral Blood Mononuclear Cells.

Thrombosis·2017
Same journal

Referral Patterns and Diagnostic Yield of Lung Scintigraphy in the Diagnosis of Acute Pulmonary Embolism.

Thrombosis·2017
Same journal

Pathogenesis of Thromboembolism and Endovascular Management.

Thrombosis·2017
Same journal

The Typical Presentation Spectrum of Deep Vein Thrombosis Associated with Inferior Vena Cava Malformations.

Thrombosis·2016
Same journal

Out of Sight, out of Mind? An Audit Which Proposes a Follow-Up and Management Pathway for Inferior Vena Cava Filters.

Thrombosis·2016
Same journal

Medicinal Herbals with Antiplatelet Properties Benefit in Coronary Atherothrombotic Diseases.

Thrombosis·2016
See all related articles

Related Experiment Video

Updated: May 21, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Factor v leiden and inflammation.

Silvia Perez-Pujol1, Omer Aras, Gines Escolar

  • 1Servicio de Hemoterapia y Hemostasia, Hospital ClĂ­nic, C/Villarroel 170, 08036 Barcelona, Spain.

Thrombosis
|June 6, 2012
PubMed
Summary
This summary is machine-generated.

Factor V Leiden (FVL) is a hypercoagulable state. This review explores FVL's role in chronic inflammatory diseases, focusing on its impact on coagulation and disease outcomes.

More Related Videos

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions
10:24

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions

Published on: June 11, 2015

Related Experiment Videos

Last Updated: May 21, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions
10:24

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions

Published on: June 11, 2015

Area of Science:

  • Hematology
  • Immunology
  • Vascular Biology

Background:

  • Factor V Leiden (FVL) is a genetic variant of factor V, leading to a hypercoagulable state.
  • Research has primarily focused on FVL's thrombotic implications.
  • The role of FVL in inflammatory conditions remains under-explored.

Purpose of the Study:

  • To review the association between Factor V Leiden and inflammatory conditions.
  • To analyze the interplay between FVL, endothelium, and immune/vascular inflammatory components.
  • To emphasize the clinical significance of FVL carriage in chronic inflammation.

Main Methods:

  • Literature review of studies investigating Factor V Leiden and inflammation.
  • Analysis of pathophysiological mechanisms linking FVL to inflammatory processes.
  • Examination of the role of endothelium and immune factors in FVL-associated inflammation.

Main Results:

  • FVL's contribution to hypercoagulability in inflammatory states is uncertain.
  • The endothelium and other inflammatory components play a role in FVL-associated inflammation.
  • FVL carriage may influence disease progression and outcomes in chronic inflammatory conditions.

Conclusions:

  • Further research is needed to elucidate the precise role of FVL in inflammation.
  • Understanding FVL's impact on inflammation is crucial for managing associated diseases.
  • FVL carriers may face altered disease trajectories in chronic inflammatory settings.